{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T21:22:28Z","timestamp":1648848148788},"reference-count":5,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2021,9,7]]},"DOI":"10.1001\/jama.2021.10648","type":"journal-article","created":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T15:01:22Z","timestamp":1631026882000},"page":"872","source":"Crossref","is-referenced-by-count":0,"title":["Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Disease Flare in Patients With Rheumatoid Arthritis"],"prefix":"10.1001","volume":"326","author":[{"given":"Kenneth Frank","family":"Baker","sequence":"first","affiliation":[{"name":"Newcastle University, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur Grant","family":"Pratt","sequence":"additional","affiliation":[{"name":"Newcastle University, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Dudley","family":"Isaacs","sequence":"additional","affiliation":[{"name":"Newcastle University, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"17","key":"jle210072r1","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1001\/jama.2021.4542","article-title":"Effect of half-dose vs stable-dose conventional synthetic disease-modifying antirheumatic drugs on disease flares in patients with rheumatoid arthritis in remission: the ARCTIC REWIND randomized clinical trial.","volume":"325","author":"Lillegraven","year":"2021","journal-title":"JAMA"},{"issue":"17","key":"jle210072r2","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1001\/jama.2021.2740","article-title":"Treatment strategies for patients with immune-mediated inflammatory diseases.","volume":"325","author":"Curtis","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"jle210072r3","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001220","article-title":"DMARD-free remission as novel treatment target in rheumatoid arthritis: a systematic literature review of achievability and sustainability.","volume":"6","author":"Verstappen","year":"2020","journal-title":"RMD Open"},{"key":"jle210072r4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.06.009","article-title":"Predicting drug-free remission in rheumatoid arthritis: a prospective interventional cohort study.","volume":"105","author":"Baker","year":"2019","journal-title":"J Autoimmun"},{"issue":"5","key":"jle210072r5","doi-asserted-by":"publisher","first-page":"e371","DOI":"10.1016\/S2665-9913(21)00069-2","article-title":"Biomarkers of tolerance in immune-mediated inflammatory diseases: a new era in clinical management?","volume":"3","author":"Baker","year":"2021","journal-title":"Lancet Rheumatol"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2783827\/jama_baker_2021_le_210072_1630095327.63616.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T15:01:25Z","timestamp":1631026885000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2783827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,7]]},"references-count":5,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9,7]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2021.10648","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,7]]}}}